SCHEMBL2066261

SCHEMBL2066261

Cc1nc(Nc2ncc(Sc3ccnc(C(=O)O)c3)s2)cc(N2CCN(CCO)CC2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 6/20 0.62
FLT3 P36888 5/20 0.62
SRC P12931 5/20 0.61
SIK2 Q9H0K1 12/20 0.60
SIK3 Q9Y2K2 12/20 0.60
ABL1 P00519 12/20 0.60
SIK1 P57059 10/20 0.60
PKMYT1 Q99640 3/20 0.56
EPHB6 O15197 2/20 0.54
EGFR P00533 2/20 0.54
LCK P06239 2/20 0.54
FYN P06241 2/20 0.54
CSF1R P07333 2/20 0.54
YES1 P07947 2/20 0.54
LYN P07948 2/20 0.54
RET P07949 2/20 0.54
HCK P08631 2/20 0.54
BCR P11274 2/20 0.54
BRAF P15056 2/20 0.54
EPHA1 P21709 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067692 0.87 SRC (0.56) KITFLT3SRCSIK2SIK3
SCHEMBL30144989 0.81 ABL1 (0.75) KITFLT3SRCSIK2SIK3
SCHEMBL3536666 0.81 ABL1 (0.75) KITFLT3SRCSIK2SIK3
SCHEMBL14141736 0.79 ABL1 (0.73) KITFLT3SRCSIK2SIK3
SCHEMBL2065878 0.78 NTRK1 (0.46) SIK2SIK3ABL1SIK1ITK
SCHEMBL27810250 0.78 SRC (0.68) KITFLT3SRCSIK2SIK3
SCHEMBL21028276 0.77 KIT (1.00) KITFLT3SRCSIK2SIK3
SCHEMBL27810247 0.77 SRC (0.65) KITFLT3SRCSIK2SIK3
SCHEMBL3844605 0.77 SRC (0.54) KITFLT3SRCSIK2SIK3
SCHEMBL3396435 0.77 ABL1 (0.73) KITFLT3SRCSIK2SIK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099794-B1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-05-15 EP disclosed
EP-2099794-B1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-05-15 EP disclosed
US-8148400-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-8148400-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-8148400-B2 Thiazolyl compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-03 US disclosed
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-25 US disclosed
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-25 US disclosed
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-25 US disclosed
EP-2099794-A2 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2009-09-16 EP disclosed
WO-2008079873-A2 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048581-A1 THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS ERBB2, TEC, TTBK1 KIT 737/4885FLT3 56/4885SRC 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.